Available via license: CC BY 4.0
Content may be subject to copyright.
A preview of the PDF is not available
Εφευρέσεις επί εμβολίων κατά του ιού SARS-CoV-2
Abstract
The rapid spread of the SARS-CoV-2 virus is the new pandemic that humanity is called upon to deal with. The special characteristics of the virus in combination with the absence of effective antiviral medication and vaccine, make the disease a significant threat to global health. This paper addresses the issue of innovation in the midst of a pandemic in the field of diagnostic and therapeutic procedures, namely vaccines for the SARS-CoV-2 virus and how these could become public goods that will be provided without expected profit, considered global public goods. The issue is so crucial for public health that the State and the international community are called upon to contribute to research and development, in terms of participating in the business risk of the industry (with public funding), but also to intervene to protection of the global good of public health, possibly considering compulsory patent licensing solutions that will result from vaccine research.
ResearchGate has not been able to resolve any citations for this publication.
The present document provides the take of innovation economists on the COVID-19 pandemic. It targets the general public and focuses on questions related to the Science, Technology, and Innovation ecosystem. It provides a reading of current real-world developments using economic reasoning and relying on existing economic research.
Vaccine candidate tested in monkeys
Global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an urgent race to develop a vaccine. Gao et al. report preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies. The researchers obtained multiple SARS-CoV-2 strains from 11 hospitalized patients across the world and then chemically inactivated the harmful properties of the virus. Animals were immunized with one of two vaccine doses and then inoculated with SARS-CoV-2. Those that received the lowest dose showed signs of controlling the infection, and those receiving the highest dose appeared more protected and did not have detectable viral loads in the pharynx or lungs at 7 days after infection. The next steps will be testing for safety and efficacy in humans.
Science , this issue p. 77
Economic implications of the COVID-19 crisis for Germany and economic policy measures
- P Bofinger
- S Dullien
- G Felbermayr
- C Fuest
- M Hüther
- J Südekum
- Weder Di Mauro
Bofinger P, Dullien S, Felbermayr G, Fuest C,
Hüther M, Südekum J, Weder di Mauro B,
Economic implications of the COVID-19 crisis
for Germany and economic policy measures, σε
As coronavirus pandemic worsens, health officials fear nationalization of drugs and supplies
- H Branswell
Branswell H, As coronavirus pandemic worsens,
health officials fear nationalization of drugs and
supplies, Stat Health, 15 March 2020.
We Need a Coronavirus Vaccine -Patents Might Slow the Process
- S Lester
Lester S, We Need a Coronavirus Vaccine -Patents Might Slow the Process, 2020.
https://www.cato.org/publications/commentary/
we-need-coronavirus-vaccine-patents-mightslow-process.